ERK1 and ERK2 are important members of the mitogen-activated protein kinases (MAPKs) family, which controls a broad range of cellular activities and physiological processes, such as proliferation, cell survival, migration, morphology determination and oncogenic transformation. The MAPK1 gene encodes the ERK2 protein, and the MAPK3 gene encodes the ERK1 protein. ERK1/2 can be activated by upstream RAS-RAF-MEK signaling. Elevated and constitutive activation of ERK1/2 has been detected in various common cancer types. Mutations in the MAPK3 and MAPK1 genes have be observed in a subset of human tumors by next generation sequencing.
The ERK genetic alteration cell panel (
ATCC TCP-1033) is composed of 7 selected human tumor cell lines from various common cancer types that carry COSMIC database validated mutations within MAPK1 and MAPK3 genes. This panel of cell lines also encompasses various basal levels of phosphor-ERK1/2.
The MAPK1 and MAPK3 gene alteration status of each cell line has been sequenced and validated by ATCC.